Galapagos is specialized in the discovery and early development of small molecule and antibody therapies with novel modes-of-action. The Company is progressing one of the largest pipelines in biotech: four programs in development and over 30 discovery programs. BioFocus, Argenta, and Fidelta the drug discovery service operations of Galapagos, lead the premium segment of the fee-for-service industry and make a substantial cash contribution to the Group.
Galapagos has a strong investor base, with a long term commitment to the biotech industry. Whether you are a current investor in Galapagos or are evaluating Galapagos as a potential investment opportunity, we welcome you to contact us should you have any additional questions after reviewing our website.